{"id":22451,"date":"2019-03-18T12:49:03","date_gmt":"2019-03-18T12:49:03","guid":{"rendered":"https:\/\/corporate.webfactory.ferring.tech\/?p=22451"},"modified":"2021-05-10T11:33:44","modified_gmt":"2021-05-10T10:33:44","slug":"ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/","title":{"rendered":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries"},"content":{"rendered":"[spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”]\n<h2 style=\"color: #0088ce;\">Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”]\n<h3 style=\"color: #0088ce;\">Saint-Prex, Switzerland \u2013 18 March 2019 \u2013<\/h3>\n<p class=\"p1\">Ferring welcomes the recent update to the World Health Organization (WHO) recommendations relating to uterotonics for the prevention of postpartum haemorrhage (PPH), with specific mention of carbetocin.<span class=\"s1\"><a href=\"#note1\"><span class=\"s2\"><sup>1<\/sup><\/span><\/a><\/span><\/p>\n<p class=\"p1\">Every year, 14 million women are affected by PPH.<a href=\"#note2\"><span class=\"s1\"><span class=\"s2\"><sup>2<\/sup><\/span><\/span><\/a>\u00a0PPH is the leading direct cause of maternal death worldwide, causing approximately 70,000 deaths per year,<span class=\"s1\">\u00a0<\/span>99% of which occur in low- and lower-middle income countries.<span class=\"s1\"><span class=\"s2\"><sup><a href=\"#note1\">1,<\/a><a href=\"#note4\">4<\/a><\/sup><\/span><\/span><\/p>\n<p class=\"p1\">Ferring is now seeking registrations for the heat-stable formulation of carbetocin* for the prevention of PPH following all births and is committed to making heat-stable carbetocin available to the public sector in low- and lower-middle income countries.<span class=\"s1\"><span class=\"s2\"><sup><a href=\"#note4\">4<\/a><\/sup><\/span><\/span>\u00a0as a priority following appropriate regulatory approval.<\/p>\n<p class=\"p1\">Once approved, the heat-stable formulation of carbetocin will be made available at an affordable and sustainable price in public-sector healthcare facilities in low- and lower-middle income countries.<span class=\"s1\"><span class=\"s2\"><sup><a href=\"#note4\">4<\/a><\/sup><\/span><\/span><span class=\"s1\">\u00a0<\/span>This price is a subsidised price of $0.31 +\/- 10% per ampoule of 100 \u00b5g heat-stable carbetocin. This price is Ex Works, which is the price at the point of leaving the manufacturing site and does not include the logistical costs of getting the medicine to healthcare providers. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).<span class=\"s1\"><a href=\"#note5\"><span class=\"s2\"><sup>5<\/sup><\/span><\/a><\/span><\/p>\n<p class=\"p1\">*The availability of investigational heat-stable carbetocin is subject to regulatory review and approval in relevant countries.<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”]\n<h3 style=\"color: #0088ce;\">About Ferring Pharmaceuticals<\/h3>\n<p class=\"p1\">Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women\u2019s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.<\/p>\n<p class=\"p1\">Learn more at\u00a0<a href=\"https:\/\/www.ferring.com\/\">www.ferring.com<\/a>, or connect with us on <a href=\"https:\/\/www.linkedin.com\/company\/ferring-pharmaceuticals\/\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.instagram.com\/ferringpharmaceuticals\/\">Instagram<\/a>,\u00a0<a href=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\">Facebook<\/a>,\u00a0<a href=\"https:\/\/twitter.com\/ferring\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.youtube.com\/channel\/UC6Ss0Uwv54xTGmM_EDEzQPA\">YouTube<\/a>.<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”]\n<h3 class=\"p1\" style=\"color: #0088ce;\">References<\/h3>\n<ol>\n<li id=\"note1\">World Health Organization. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Published 2018. Available at: <a href=\"https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277276\/9789241550420-eng.pdf?ua=1\">http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277276\/9789241550420-eng.pdf?ua=1<\/a> Last accessed: March 2019.<\/li>\n<li id=\"note2\">World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: <a href=\"https:\/\/www.who.int\/medicines\/areas\/priority_medicines\/Ch6_16PPH.pdf\">https:\/\/www.who.int\/medicines\/areas\/priority_medicines\/Ch6_16PPH.pdf<\/a> Last accessed: March 2019.<\/li>\n<li id=\"note3\">Say L, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014; 2(6):e323-33. Available at: <a href=\"https:\/\/doi.org\/10.1016\/S2214-109X(14)70227-X\">https:\/\/doi.org\/10.1016\/S2214-109X(14)70227-X<\/a> \u00a0Last accessed: March 2019.<\/li>\n<li id=\"note4\">World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groupsLast accessed: March 2019<\/li>\n<li id=\"note5\">UNFPA Product Catalog, accessed 25 July 2019 <a href=\"https:\/\/www.unfpaprocurement.org\/products?id=OXYTOCIN_10IU\/ML\">https:\/\/www.unfpaprocurement.org\/products?id=OXYTOCIN_10IU\/ML<\/a><\/li>\n<\/ol>\n[\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”]\n<div class=\"downloadRows\">\n<div><\/div>\n<div class=\"rowss\"><a href=\"https:\/\/www.ferring.com\/wp-content\/uploads\/sites\/16\/2019\/06\/hsc-pricing-statement_french-mar-2019-1.pdf\"><br \/>\n<i>French Press Release<\/i><img decoding=\"async\" src=\"\/wp-content\/uploads\/sites\/16\/2019\/10\/Sans-titre-1-1.png\" width=\"25px\" \/><\/a><\/div>\n<\/div>\n<div><\/div>\n[\/spb_boxed_content]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries [\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Saint-Prex, Switzerland \u2013 18 March 2019 \u2013 Ferring welcomes the recent update to the World Health Organization (WHO) […]<\/p>\n","protected":false},"author":2410,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[242],"tags":[],"class_list":["post-22451","post","type-post","status-publish","format-standard","hentry","category-press-release-2019"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries [\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Saint-Prex, Switzerland \u2013 18 March 2019 \u2013 Ferring welcomes the recent update to the World Health Organization (WHO) […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-18T12:49:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-10T10:33:44+00:00\" \/>\n<meta name=\"author\" content=\"pulse\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"pulse\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\"},\"author\":{\"name\":\"pulse\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\"},\"headline\":\"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries\",\"datePublished\":\"2019-03-18T12:49:03+00:00\",\"dateModified\":\"2021-05-10T10:33:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"articleSection\":[\"PRESS RELEASE 2019\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\",\"url\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\",\"name\":\"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"datePublished\":\"2019-03-18T12:49:03+00:00\",\"dateModified\":\"2021-05-10T10:33:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\",\"name\":\"pulse\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"caption\":\"pulse\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/","og_locale":"en_US","og_type":"article","og_title":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries","og_description":"[spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries [\/spb_boxed_content] [spb_blank_spacer height=”30px” width=”1\/1″ el_position=”first last”] [spb_boxed_content type=”coloured” box_link_target=”_self” padding_vertical=”0″ padding_horizontal=”0″ width=”1\/1″ el_position=”first last”] Saint-Prex, Switzerland \u2013 18 March 2019 \u2013 Ferring welcomes the recent update to the World Health Organization (WHO) […]","og_url":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2019-03-18T12:49:03+00:00","article_modified_time":"2021-05-10T10:33:44+00:00","author":"pulse","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"pulse","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/"},"author":{"name":"pulse","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d"},"headline":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries","datePublished":"2019-03-18T12:49:03+00:00","dateModified":"2021-05-10T10:33:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/"},"wordCount":650,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"articleSection":["PRESS RELEASE 2019"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/","url":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/","name":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"datePublished":"2019-03-18T12:49:03+00:00","dateModified":"2021-05-10T10:33:44+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/ferring-statement-on-subsidised-pricing-of-heat-stable-carbetocin-for-the-prevention-of-postpartum-haemorrhage-in-low-and-lower-middle-income-countries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d","name":"pulse","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","caption":"pulse"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22451"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/2410"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=22451"}],"version-history":[{"count":0,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=22451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=22451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=22451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}